Literature DB >> 8228200

The kidney and essential hypertension: a link to osteoporosis?

G A MacGregor1, F P Cappuccio.   

Abstract

INTRODUCTION: Abnormalities of calcium metabolism independent of changes in intracellular calcium have been described in patients with essential hypertension. These include increased urinary calcium excretion for a given salt intake, a raised parathyroid hormone level, an increase in urinary cyclic AMP, a tendency for a low serum ionized calcium level, a raised 1,25-dihydroxyvitamin D level and an increased intestinal calcium reabsorption. These changes have been seen as a consequence of a primary renal calcium leak. HYPOTHESIS: We propose that these changes are secondary to a genetic defect in the ability of the kidney to excrete sodium. On the high salt intake in most Western countries (i.e. approximately 170 mmol/day sodium) compensatory mechanisms occur to try to overcome this defect. These compensatory mechanisms are responsible for the rise in blood pressure, but also cause an increase in central blood volume which is the direct cause of the increase in urinary calcium excretion. This causes a slightly negative calcium balance, and the other abnormalities of calcium metabolism can then be seen as a compensatory response to try to restore calcium balance to normal. DISCUSSION: This hypothesis explains the increase in kidney stones in essential hypertension and predicts that hypertensives, in the long term, will be more likely to develop bone demineralization (osteoporosis), as has been demonstrated in some animal models of hypertension. Increases in salt intake will not only cause a further rise in blood pressure, but will also increase urinary calcium excretion and aggravate the other abnormalities. A moderate reduction in salt intake from 170 to 70 mmol/day will lower the blood pressure and will tend to correct the abnormalities of calcium metabolism. It should simultaneously reduce the incidence of renal stones and the long-term risk of bone demineralization.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228200     DOI: 10.1097/00004872-199308000-00003

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  17 in total

Review 1.  The DASH trials implicate dysfunction in calcium regulation in the pathogenesis of human hypertension.

Authors:  A G Logan
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

2.  'With a pinch of salt' revisited.

Authors:  Francesco P Cappuccio
Journal:  Clin Med (Lond)       Date:  2010-10       Impact factor: 2.659

3.  Meta-analysis of hypertension and osteoporotic fracture risk in women and men.

Authors:  C Li; Y Zeng; L Tao; S Liu; Z Ni; Q Huang; Q Wang
Journal:  Osteoporos Int       Date:  2017-04-26       Impact factor: 4.507

4.  A susceptibility haplotype within the endothelial nitric oxide synthase gene influences bone mineral density in hypertensive women.

Authors:  Monica Singh; Puneetpal Singh; Surinder Singh; Pawan Kumar Juneja; Taranpal Kaur
Journal:  J Bone Miner Metab       Date:  2013-11-10       Impact factor: 2.626

5.  Computational analysis of candidate disease genes and variants for salt-sensitive hypertension in indigenous Southern Africans.

Authors:  Nicki Tiffin; Ayton Meintjes; Rajkumar Ramesar; Vladimir B Bajic; Brian Rayner
Journal:  PLoS One       Date:  2010-09-27       Impact factor: 3.240

6.  Association between hypertension and fragility fracture: a longitudinal study.

Authors:  S Yang; N D Nguyen; J R Center; J A Eisman; T V Nguyen
Journal:  Osteoporos Int       Date:  2013-07-27       Impact factor: 4.507

Review 7.  Relationship between vitamin D deficiency and cardiovascular disease.

Authors:  Yan-Chiou Ku; Mu-En Liu; Chang-Sheng Ku; Ta-Yuan Liu; Shoa-Lin Lin
Journal:  World J Cardiol       Date:  2013-09-26

8.  Effects of enalapril and hydrochlorothiazide on the salt-induced cardiac and renal hypertrophy in normotensive rats.

Authors:  E M Mervaala; J Laakso; H Vapaatalo; H Karppanen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-10       Impact factor: 3.000

9.  Reciprocal roles of angiotensin II and Angiotensin II Receptors Blockade (ARB) in regulating Cbfa1/RANKL via cAMP signaling pathway: possible mechanism for hypertension-related osteoporosis and antagonistic effect of ARB on hypertension-related osteoporosis.

Authors:  Xiao-Xu Guan; Yi Zhou; Ji-Yao Li
Journal:  Int J Mol Sci       Date:  2011-06-27       Impact factor: 5.923

10.  Determining the association between hypertension and bone metabolism markers in osteoporotic patients.

Authors:  Zhuoqing Hu; Kevin Yang; Zhihui Hu; Miaosheng Li; Hao Wei; Zheng Tang; Baitong Chen; Chengbiao Su; Jinrong Xu
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.